These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Ward LM; Rauch F; White KE; Filler G; Matzinger MA; Letts M; Travers R; Econs MJ; Glorieux FH Bone; 2004 May; 34(5):905-11. PubMed ID: 15121023 [TBL] [Abstract][Full Text] [Related]
23. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy. Takashi Y; Kinoshita Y; Hori M; Ito N; Taguchi M; Fukumoto S Endocr Res; 2017 May; 42(2):132-137. PubMed ID: 27754732 [TBL] [Abstract][Full Text] [Related]
24. [FGF23-related hypophosphatemic rickets/osteomalacia]. Ito N; Fukumoto S Clin Calcium; 2007 Oct; 17(10):1514-20. PubMed ID: 17906402 [TBL] [Abstract][Full Text] [Related]
25. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. Imel EA; Hui SL; Econs MJ J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222 [TBL] [Abstract][Full Text] [Related]
26. Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. El-Maouche D; Dumitrescu CE; Andreopoulou P; Gafni RI; Brillante BA; Bhattacharyya N; Fedarko NS; Collins MT Osteoporos Int; 2016 Jul; 27(7):2345-2353. PubMed ID: 26928188 [TBL] [Abstract][Full Text] [Related]
27. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. Smith ER; McMahon LP; Holt SG Clin Chem Lab Med; 2013 Oct; 51(10):1971-81. PubMed ID: 23729624 [TBL] [Abstract][Full Text] [Related]
28. [Clinical usefulness of the determination of fibroblast growth factor 23 in the evaluation of patients with osteomalacia]. Gifre L; Martínez de Osaba MJ; Monegal A; Guañabens N; Peris P Med Clin (Barc); 2014 May; 142(10):447-50. PubMed ID: 24629692 [TBL] [Abstract][Full Text] [Related]
29. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Kobayashi K; Imanishi Y; Koshiyama H; Miyauchi A; Wakasa K; Kawata T; Goto H; Ohashi H; Koyano HM; Mochizuki R; Miki T; Inaba M; Nishizawa Y Life Sci; 2006 Apr; 78(20):2295-301. PubMed ID: 16337659 [TBL] [Abstract][Full Text] [Related]
30. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia? Lee EK; Martinez MC; Blakely K; Santos KD; Hoang VC; Chow A; Emmenegger U Med Hypotheses; 2014 Oct; 83(4):482-7. PubMed ID: 25155552 [TBL] [Abstract][Full Text] [Related]
31. FGF23-related hypophosphatemia in patients with low bone mineral density and fragility fractures: challenges in diagnosis and management. Indirli R; Guabello G; Longhi M; Niada S; Maruca K; Mora S; Maggioni M; Corbetta S J Endocrinol Invest; 2020 Jun; 43(6):787-798. PubMed ID: 31863362 [TBL] [Abstract][Full Text] [Related]
32. Structural and biochemical properties of fibroblast growth factor 23. Yamashita T Ther Apher Dial; 2005 Aug; 9(4):313-8. PubMed ID: 16076373 [TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor 23 and its receptors. Yu X; White KE Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372 [TBL] [Abstract][Full Text] [Related]
34. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice. Du E; Xiao L; Hurley MM J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296 [TBL] [Abstract][Full Text] [Related]
35. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis. Goldsweig BK; Carpenter TO Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749 [TBL] [Abstract][Full Text] [Related]
36. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of a new automated chemiluminescence immunoassay for FGF23. Shimizu Y; Fukumoto S; Fujita T J Bone Miner Metab; 2012 Mar; 30(2):217-21. PubMed ID: 21898178 [TBL] [Abstract][Full Text] [Related]
38. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. Yamamoto T; Imanishi Y; Kinoshita E; Nakagomi Y; Shimizu N; Miyauchi A; Satomura K; Koshiyama H; Inaba M; Nishizawa Y; Jüppner H; Ozono K J Bone Miner Metab; 2005; 23(3):231-7. PubMed ID: 15838626 [TBL] [Abstract][Full Text] [Related]
39. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782 [TBL] [Abstract][Full Text] [Related]